Lamotrigine
4.1 Therapeutic indications
Epilepsy:
Adults and adolescents aged 13 years and above
• Adjunctive or monotherapy treatment of partial seizures and generalized seizures, including tonic-clonic seizures.
• Seizures associated with Lennox-Gastaut syndrome. Lamotrigine is given as an adjunctive therapy but may be the initial antiepileptic drug (AED) to start with in Lennox-Gastaout syndrome.
Children and adolescents aged 2 to 12 years
• Adjunctive treatment of partial seizures and generalized seizures, including tonic-clonic seizures and the seizures associated with Lennox-Gastaut syndrome.
• Monotherapy of typical absence seizures.
Bipolar disorder:
Adults aged 18 years and above
• Prevention of depressive episodes in patients with bipolar I disorder who experience predominantly depressive episodes (see section 5.1).
Lamotrigine is not indicated for the acute treatment of manic or depressive episodes.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
Disclaimer
The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.
Medthority will not be held liable for explicit or implicit errors, or missing data.
Drug Licencing
Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).